Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q3 2020 · 10-Q
Revenue—
Net Income-$3.01M-$3.01MN/M vs Q3 2019 EPS Diluted-$0.03-$0.03N/M vs Q3 2019 Operating Income-$11,879,178N/M Operating Cash Flowderived-$5,955,494N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
ended Jun 30, 2020 · filed Aug 14, 2020 · 45 d after period end